It has been uncovered in a recent report that Pfizer, a research-based pharmaceutical company, has got the approval of the FDA (Food and Drug Administration) for a new drug INLYTA (axitinib). The report says that the drug is highly beneficial for the patients with advanced RCC or Renal Cell Carcinoma.

Recent reports have revealed that the residents of Macedon Ranges might have to wait for even the very basic medicines as Pfizer; the drug giant is coming up with its exclusive supply chain of products.

This major shift might mean that the pharmacists might now have to take separate orders for items such as contraceptive pills and so on.

Amid rising concern over collapse of Viagra's patent on June 18, demand for other generic erectile dysfunction drugs is expected to take a jump. With the news hitting the corners of medical fraternity, many companies in Finland and Italy shifted to other drugs to meet rising patient’s demand.

New York-based pharmaceutical giant Pfizer, seeking approval for the marketing of axitinib as a treatment for advanced renal cell carcinoma (RCC) for patients who failed to benefit from systemic treatment, has filed the oral drug with the European Medicines Agency!

Having a healthy sex life will soon be more affordable for men with erectile dysfunction living in New Zealand. Pfizer, the drug company that makes Viagra (sildenafil citrate) will release a generic version of Viagra in New Zealand called Avigra when Viagra’s patent for New Zealand expires in June.

An incorrect labeling by a third-party manufacturer forced Pfizer’s Greenstone LLC subsidiary to announce the voluntary recall two drugs – depression drug Citalopram; and benign prostatic hyperplasia drug Finasteride - in the US on Saturday!

The recall resulted from an inadvertent ‘label switch’ which affected the two generic formulations - the antidepressant drug and the one used for shrinking the prostate.